Traditional Chinese medicine composition and traditional Chinese medicine preparation for improving leucopenia and intestinal mucosa damage caused by chemotherapy as well as preparation method and application of traditional Chinese medicine preparation
Through traditional Chinese medicine compositions of Tremella, Ganoderma lucidum and Polygonatum, combined with enzymatic extraction technology, a traditional Chinese medicine preparation that can improve leukopenia and intestinal mucosa damage caused by chemotherapy was prepared, which solved the problem of side effects of chemotherapy, achieved improvement of immunity and reduced adverse reactions effect.
Patent Information
- Application Number
- CN202411209155.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-06
AI Technical Summary
Chemotherapy leads to leukopenia and damage to the intestinal mucosa. The existing technology is difficult to effectively solve these side effects, and traditional combination treatment plans bring new adverse effects.
Provided a traditional Chinese medicine composition, including Tremella, Ganoderma lucidum and Polygonatum, prepares a traditional Chinese medicine preparation by enzyme preparation extraction and multi-step treatment, for improving leukopenia and intestinal mucosa damage caused by chemotherapy. The preparation method includes primary drying, crushing, and enzymatic decomposition. Extract, concentrate and dry to form orally-administered Chinese medicine preparations.
The traditional Chinese medicine composition and preparation can effectively improve the reduction of leukocyte count and intestinal mucosa damage caused by chemotherapy, improve immunity, and have the characteristics of no side effects, high stability, long shelf life, reliable efficacy and easy transportation.
Smart Images

Figure CN119074855A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to the technical field of traditional Chinese medicine, for example, to a traditional Chinese medicine composition for improving chemotherapy-induced leukopenia and intestinal mucosal damage, a traditional Chinese medicine preparation, and a preparation method and application thereof. Background Art
[0002] Chemotherapy (i.e., chemotherapy) is an important part of oncology treatment and is currently the third largest treatment for malignant tumors. Chemotherapy not only specifically kills tumor cells, but also has a nonspecific killing effect on healthy cells, which leads to a decrease in the number of white blood cells in the body's peripheral blood, an immunosuppressive effect on the body's important immune organs, and low immunity in patients. In addition, chemotherapy can also cause damage to the gastrointestinal barrier and clinical symptoms of gastrointestinal dysfunction such as nausea, vomiting, diarrhea, and constipation. The intestine is the largest digestive organ and immune organ in the human body, which can resist the invasion of harmful substances and pathogens. However, chemotherapy can cause intestinal flora disorders and loss of integrity of intestinal epithelial structure, which in turn leads to reduced intestinal immunoglobulin secretion, weakened intestinal barrier function, and bacterial migration, ultimately aggravating the body's immunosuppressive effect. Traditional Chinese medicine believes that chemotherapy belongs to the category of "drug poison", which is very easy to damage the spleen and stomach, the spleen's transportation and transformation function is damaged, and the stomach qi does not descend, resulting in symptoms such as abdominal distension and nausea and vomiting. The spleen and stomach are the source of Qi and blood production. Chemotherapy causes damage to the spleen and stomach function and insufficient Qi and blood production, resulting in symptoms of Qi and blood deficiency such as fatigue, pale complexion, shortness of breath and poor appetite.
[0003] In the process of treating tumors, side effects such as leukopenia and intestinal mucosal damage have become the main reasons for chemotherapy interruption. In order to cope with this defect of chemotherapy drugs, the current main use of chemotherapy drugs, local application, combined with immunosuppressants and other dosing schemes to reduce drug toxicity and side effects. However, although these combined treatment schemes can reduce the damage of chemotherapy drugs to the body, they also bring new adverse reactions to a greater or lesser extent. Therefore, it has become a top priority to find new, highly effective and low-toxic drugs to fight malignant tumors.
[0004] Long-term clinical practice has proved that Chinese medicine has obvious effects in replenishing blood and enhancing patients' immunity, and its efficacy and advantages have gradually been recognized. Chinese medicine has low toxicity and good efficacy, so the development of traditional, safe and effective Chinese medicine prescriptions has great development potential as an adjuvant treatment after chemotherapy. In summary, it is of great significance to develop a Chinese medicine prescription that can improve chemotherapy-induced leukopenia and intestinal mucosal damage. Summary of the invention
[0005] The purpose of the present invention is to overcome the deficiencies in the prior art and to provide a Chinese medicine composition, a Chinese medicine preparation, and a preparation method and application thereof for improving chemotherapy-induced leukopenia and intestinal mucosal damage, so as to at least achieve the effect of not only improving chemotherapy-induced leukopenia and intestinal mucosal damage, but also improving immunity.
[0006] The purpose of this disclosure is achieved through the following technical solutions:
[0007] In one aspect, a Chinese medicine composition for improving chemotherapy-induced leukopenia and intestinal mucosal damage is provided. The raw materials of the Chinese medicine composition include 7.5 to 30 parts of Tremella fuciformis, 5 to 20 parts of Ganoderma lucidum and 3 to 12 parts of Polygonatum sibiricum by weight.
[0008] In some examples, the raw materials include 30 parts of Tremella fuciformis, 20 parts of Ganoderma lucidum and 12 parts of Polygonatum sibiricum, by weight.
[0009] In other examples, the raw materials include 15 parts of Tremella fuciformis, 10 parts of Ganoderma lucidum and 6 parts of Polygonatum sibiricum by weight.
[0010] In another aspect, a Chinese medicine preparation for improving chemotherapy-induced leukopenia and intestinal mucosal damage is provided, wherein the Chinese medicine preparation is prepared from the Chinese medicine composition described in any one of the above embodiments.
[0011] In some embodiments, the dosage form of the traditional Chinese medicine preparation includes at least one of oral liquid, capsule and granule.
[0012] It should be understood that there are multiple methods for preparing the oral liquid, the capsule or the granule of the traditional Chinese medicine preparation, and those skilled in the art can make adaptive selections as needed, and the present disclosure does not limit this.
[0013] In some examples, the oral liquid, the capsule or the granule of the traditional Chinese medicine preparation can be prepared according to the corresponding method recorded in the 2020 edition of the "Chinese Pharmacopoeia".
[0014] In another aspect, a method for preparing the Chinese medicine preparation as described in any one of the above embodiments is provided. The method comprises: pre-drying, crushing and screening the raw material to obtain a powder; mixing the enzyme preparation and water with the powder, performing heat preservation and enzymatic extraction, then heating for re-extraction, and then centrifuging and filtering to obtain a filtrate; and concentrating, sterilizing and re-drying the filtrate to obtain the Chinese medicine preparation.
[0015] In some embodiments, the enzyme preparation comprises Viscozyme L and β-glucanase.
[0016] In some examples, the mass concentration of Viscozyme L is 1%.
[0017] In some examples, the mass concentration of the β-glucanase is 1%.
[0018] It should be understood that the Viscozyme L and the β-glucanase involved in the embodiments of the present disclosure are both known products and can be obtained by purchasing commercial products.
[0019] In some embodiments, the mass ratio of the enzyme preparation, the water and the powder is 1:500-1000:50-100.
[0020] In some examples, the mass ratio of the enzyme preparation, the water, and the powder is 1:1000:100.
[0021] In some embodiments, the temperature of the heat preservation enzymatic extraction is 45 to 55° C., and the time of the heat preservation enzymatic extraction is 1 to 3 hours.
[0022] In some examples, the temperature of the incubation enzymatic extraction is 50° C., and the time of the incubation enzymatic extraction is 2 hours.
[0023] In some embodiments, the temperature of the re-extraction is 75-85° C., and the time of the re-extraction is 1-3 hours.
[0024] In some examples, the re-extraction temperature is 80° C., and the re-extraction time is 1 hour.
[0025] In some embodiments, the screening includes: passing through a 40-60 mesh sieve.
[0026] In some examples, the screening includes: passing through a 60-mesh screen.
[0027] In some examples, the re-drying includes at least one of spray drying and low temperature vacuum drying.
[0028] Exemplarily, the re-drying is the spray drying.
[0029] On the other hand, a Chinese medicine composition as described in any one of the above embodiments, or a Chinese medicine preparation as described in any one of the above embodiments, or a method as described in any one of the above embodiments is provided for use in preparing at least one of a drug, a health product and a food for improving leukopenia and / or intestinal mucosal damage caused by chemotherapy.
[0030] In summary, the Chinese medicine composition provided by the present invention is based on the understanding and treatment principles of traditional Chinese medicine on the damage caused by chemotherapy, combined with the achievements of modern pharmacological research. In detail: the Tremella has the effects of nourishing the spleen and appetizing, nourishing the lungs and replenishing qi, nourishing yin and moistening dryness, and has the effect of replenishing qi and clearing the intestines, and is often used for physical weakness after illness; the Ganoderma lucidum has the effects of nourishing the heart and calming the mind, replenishing qi and blood, replenishing the lungs and relieving asthma, nourishing and strengthening, and strengthening the body, and is often used to improve immunity; the Polygonatum sibiricum belongs to the tonic Chinese medicine, which is sweet in taste, neutral in nature, and enters the spleen, lung, and kidney meridians, and has the effects of protecting organs, regulating immunity, anti-oxidation, and treating tumors.
[0031] It is worth noting that the Tremella fuciformis, the Ganoderma lucidum and the Polygonatum sibiricum in the traditional Chinese medicine composition provided by the present invention have a synergistic effect in improving leukopenia and intestinal mucosal damage caused by chemotherapy, that is, the improvement effect achieved by the combined use of the Tremella fuciformis, the Ganoderma lucidum and the Polygonatum sibiricum is greater than the sum of the improvement effects achieved by the separate use of the Tremella fuciformis, the Ganoderma lucidum and the Polygonatum sibiricum.
[0032] The beneficial effects of the present disclosure are:
[0033] 1. The raw materials of the Chinese medicine composition provided by the present invention are all Chinese medicines that can be used as both medicine and food, and have reliable efficacy and no side effects.
[0034] 2. The Chinese medicine preparation provided by the present disclosure is a compound preparation, which has the effect of improving leukopenia and intestinal mucosal damage caused by chemotherapy, and has reliable efficacy and no side effects.
[0035] 3. The Chinese medicine preparation provided by the present disclosure has the characteristics of stable properties and long shelf life, and can be completely soluble in water.
[0036] 4. The preparation method of the Chinese medicine preparation provided by the present invention is simple, and can be made into a pharmaceutically acceptable dosage form, which is convenient for clinical use and transportation, has high quality, less pollution and little side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] In order to more clearly illustrate the technical solutions in the present disclosure, the following briefly introduces the drawings required to be used in some embodiments of the present disclosure. Obviously, the drawings described below are only drawings of some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can also be obtained based on these drawings. In addition, the drawings described below can be regarded as schematic diagrams, and are not limitations on the actual process of the method involved in the embodiments of the present disclosure.
[0038] Figure 1 This is a comparison chart of the colon lengths of the chemotherapy mice in each group in Section 5 of the experimental examples disclosed herein;
[0039] Figure 2This is a comparison of the colon morphology of each group of chemotherapy mice in Section 6 of the disclosed experimental examples (HE staining, 200×). DETAILED DESCRIPTION
[0040] The technical solutions in some embodiments of the present disclosure are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present disclosure, not all of the embodiments. Based on the embodiments provided by the present disclosure, all other embodiments obtained by ordinary technicians in this field belong to the scope of protection of the present disclosure.
[0041] Unless the context requires otherwise, throughout the specification and claims, the term "comprising" is to be construed in an open, inclusive sense, ie, meaning "including, but not limited to."
[0042] When describing some embodiments, the expressions "at least one of A, B and C" and "at least one of A, B or C" may be used, both of which have the same meaning and include the following combinations of A, B and C: A only, B only, C only, the combination of A and B, the combination of A and C, the combination of B and C, and the combination of A, B and C.
[0043] Example 1
[0044] 1. A Chinese medicine composition for improving leukopenia and intestinal mucosal damage caused by chemotherapy, wherein the raw materials include 15 parts of Tremella fuciformis, 10 parts of Ganoderma lucidum and 6 parts of Polygonatum sibiricum by weight.
[0045] 2. A Chinese medicine preparation for improving chemotherapy-induced leukopenia and intestinal mucosal damage, prepared from the above Chinese medicine composition, and the preparation method thereof comprises:
[0046] S1. Weigh the above raw materials and dry and crush them, then pass through a 60-mesh sieve to obtain a powder;
[0047] S2. The enzyme preparation, water and powder were mixed in a mass ratio of 1:1000:100, and the mixture was subjected to enzymatic extraction at 50°C for 2 hours, and the mixture was heated to 80°C for extraction again for 1 hour, and then centrifuged and filtered to obtain a filtrate; wherein the enzyme preparation included Viscozyme L and β-glucanase at a mass concentration of 1% each;
[0048] S3. Concentrate, sterilize and spray-dry the filtrate to obtain the product.
[0049] Comparative Example 1
[0050] Example 1 was compared with Control Example 1, wherein Control Example 1 differed from Example 1 in that the raw materials of the Chinese medicine composition only included 15 portions of Tremella fuciformis, and other conditions such as the preparation steps and condition parameters of the Chinese medicine preparation were the same as those of Example 1 (compared with Example 1, Ganoderma lucidum and Polygonatum sibiricum were not added to the raw materials of the Chinese medicine composition in this Control Example, which was used to prove that the Chinese medicine composition provided by the present disclosure has better effects).
[0051] Comparative Example 2
[0052] Example 1 was compared with Control Example 2, wherein Control Example 2 differed from Example 1 in that the raw materials of the Chinese medicine composition only included 10 portions of Ganoderma lucidum, and other conditions such as the preparation steps and condition parameters of the Chinese medicine preparation were the same as those of Example 1 (compared with Example 1, Tremella fuciformis and Polygonatum sibiricum were not added to the raw materials of the Chinese medicine composition in this Control Example, which was used to prove that the Chinese medicine composition provided by the present disclosure has better effects).
[0053] Comparative Example 3
[0054] Example 1 was compared with Control Example 3, wherein Control Example 3 differed from Example 1 in that the raw materials of the Chinese medicine composition only included 6 portions of Polygonatum sibiricum, and other conditions such as the preparation steps and condition parameters of the Chinese medicine preparation were the same as those of Example 1 (compared with Example 1, Tremella fuciformis and Ganoderma lucidum were not added to the raw materials of the Chinese medicine composition in this Control Example, in order to prove that the Chinese medicine composition provided by the present disclosure has better effects).
[0055] Experimental example
[0056] 1. Animal grouping, modeling and drug treatment
[0057] Six-week-old Balb / c mice, half male and half female, were randomly divided into 8 groups according to body weight, with 10 mice in each group, namely, a blank control group, a model group (100 mg / kg cyclophosphamide was intraperitoneally injected for 3 consecutive days), a low-dose group (100 mg / kg cyclophosphamide was intraperitoneally injected for 3 consecutive days, followed by continuous gavage of the Chinese medicine preparation prepared in Example 1 at a dose of 2 g / kg), a medium-dose group (100 mg / kg cyclophosphamide was intraperitoneally injected for 3 consecutive days, followed by continuous gavage of the Chinese medicine preparation prepared in Example 1 at a dose of 4 g / kg), and a high-dose group (100 mg / kg cyclophosphamide was intraperitoneally injected for 3 consecutive days). g / kg cyclophosphamide followed by continuous gavage at a dose of 8g / kg for the Chinese medicine preparation prepared in Example 1), a first control group (the Chinese medicine preparation prepared in Control Example 1 after continuous gavage at a dose of 8g / kg for 3 consecutive days after intraperitoneal injection of 100mg / kg cyclophosphamide), a second control group (the Chinese medicine preparation prepared in Control Example 2 after continuous gavage at a dose of 8g / kg for 3 consecutive days after intraperitoneal injection of 100mg / kg cyclophosphamide) and a third control group (the Chinese medicine preparation prepared in Control Example 3 after continuous gavage at a dose of 8g / kg for 3 consecutive days after intraperitoneal injection of 100mg / kg cyclophosphamide).
[0058] 2. Determination of thymic index
[0059] The thymus of each group of mice was collected, and the thymus index of each group of mice was calculated according to the thymus mass and body weight before sacrifice. The calculation formula is as follows:
[0060] Thymus index (mg / g) = thymus mass (mg) / body mass (g).
[0061] The results are shown in Table 1. In the low-dose group, medium-dose group, and high-dose group, the thymus indexes of the chemotherapy mice were 0.88±0.36, 0.89±0.31, and 1.06±0.44, respectively, and the differences compared with the model group were statistically significant (P<0.05); in the high-dose group, the thymus index of the chemotherapy mice was higher than that of the first control group, the second control group, and the third control group, which indicates that the effect of the medicine-food compound of Example 1 is better than that of the single drugs of Control Examples 1 to 3; in addition, compared with the model group, the thymus index of the high-dose group increased by 0.69, which is better than the sum of the increases of the first control group, the second control group, and the third control group by 0.66, which indicates that the medicine-food compound of Example 1 has a synergistic effect on the thymus index of mice after chemotherapy.
[0062] Table 1 Effects of each group of Chinese medicine preparations on the thymus index of chemotherapy mice
[0063]
[0064] Note: * indicates P < 0.05 compared with the model group; ** indicates P < 0.01 compared with the model group; *** indicates P < 0.001 compared with the model group; **** indicates P < 0.0001 compared with the model group.
[0065] 3. Blood cell count
[0066] After collecting blood from the mouse orbit, add an appropriate amount of whole blood to an EDTA-K2 anticoagulant tube and mix well. Use a three-differentiation animal blood cell analyzer to determine the number and proportion of leukocytes and lymphocytes in the mouse peripheral blood.
[0067] The results are shown in Table 2. In the high-dose group, the number of leukocytes in the peripheral blood of chemotherapy mice was (10.56±3.00)×10 9 / L, higher than the model group (5.80±1.44)×10 9 / L, the differences were statistically significant (P<0.01); in the high-dose group, the number of leukocytes in the peripheral blood of chemotherapy mice was higher than that of the first control group, the second control group and the third control group, which shows that the effect of the medicine-food compound of Example 1 is better than the single drug of Control Examples 1 to 3; in addition, compared with the model group, the number of leukocytes in the peripheral blood of the high-dose group increased by 4.76, which is better than the sum of the increases of 3.14 in the first control group, the second control group and the third control group, which shows that the medicine-food compound of Example 1 has a synergistic effect on the number of leukocytes in mice after chemotherapy.
[0068] In the medium-dose group and the high-dose group, the percentage of lymphocytes in the peripheral blood of the chemotherapy mice was 41.70±12.90 and 48.52±12.40, which was higher than 22.20±5.42 in the model group, and the differences were statistically significant (P<0.01); in the high-dose group, the percentage of lymphocytes in the peripheral blood of the chemotherapy mice was higher than that of the first control group, the second control group and the third control group, which shows that the effect of the medicine-food compound of Example 1 is better than the single drug of Control Examples 1 to 3; in addition, compared with the model group, the percentage of lymphocytes in the peripheral blood of the high-dose group increased by 26.32, which is better than the sum of the increases of 16.52 in the first control group, the second control group and the third control group, which shows that the medicine-food compound of Example 1 has a synergistic effect on the percentage of lymphocytes in mice after chemotherapy.
[0069] Table 2 Effects of each group of Chinese medicine preparations on the number of blood cells in chemotherapy mice
[0070]
[0071] Note: * indicates P < 0.05 compared with the model group; ** indicates P < 0.01 compared with the model group; *** indicates P < 0.001 compared with the model group; **** indicates P < 0.0001 compared with the model group.
[0072] 4. T cell and B cell proliferation capacity determination
[0073] Mouse spleen was isolated under sterile conditions, and spleen single cell suspension was prepared after grinding, lysing red blood cells, and washing, and the cell concentration was adjusted to 1×10 6 / mL, add 100μL of spleen cell suspension to the 96-well plate. Add LPS (10μg / mL) or ConA (2μg / mL) to each group, culture and induce for 48h in a 37℃, 5% CO2 incubator. 4h before the end of culture, add 10μL CCK-8 solution and continue to culture for 4h. Detect the absorbance (A) value at a wavelength of 450nm using an enzyme reader (450nm).
[0074] Calculate T cell proliferation capacity = (AconA -A 空白 ) / (A 对照 -A 空白 )
[0075] Calculate the proliferation capacity of B cells = (A LPS -A 空白 ) / (A 对照 -A 空白 )
[0076] The results are shown in Table 3. In the low-dose group, medium-dose group, and high-dose group, the T cell proliferation ability of chemotherapy mice was 1.04±0.42, 1.08±0.25, and 1.17±0.15, respectively, and the differences compared with the model group were statistically significant (P<0.05); in the high-dose group, the T cell proliferation ability of chemotherapy mice was higher than that of the first control group, the second control group, and the third control group, which shows that the effect of the medicine-food compound of Example 1 is better than the single drug of Control Examples 1 to 3; in addition, compared with the model group, the T cell proliferation ability of the high-dose group increased by 0.70, which is better than the sum of the increases of the first control group, the second control group, and the third control group by 0.37, which shows that the medicine-food compound of Example 1 has a synergistic effect on the T cell proliferation ability of mice after chemotherapy.
[0077] In the low-dose group, medium-dose group, and high-dose group, the B cell proliferation capacity of chemotherapy mice was 0.96±0.23, 0.98±0.21, and 1.22±0.31, respectively, and the differences compared with the model group were statistically significant (P<0.05); in the high-dose group, the B cell proliferation capacity of chemotherapy mice was higher than that of the first control group, the second control group, and the third control group, which indicates that the effect of the medicine-food compound of Example 1 is better than the single drug of Control Examples 1 to 3; in addition, compared with the model group, the B cell proliferation capacity of the high-dose group increased by 0.71, which is better than the sum of the increases of the first control group, the second control group, and the third control group by 0.63, which indicates that the medicine-food compound of Example 1 has a synergistic effect on the B cell proliferation capacity of mice after chemotherapy.
[0078] Note: * indicates P < 0.05 compared with the model group; ** indicates P < 0.01 compared with the model group; *** indicates P < 0.001 compared with the model group; **** indicates P < 0.0001 compared with the model group.
[0079] 5. Colon Length Measurement
[0080] After autopsy, the length of each mouse's colon (from the end of the cecum to the end of the colon) was measured and typical pictures were selected for photographing. The higher the level of inflammation, the shorter the length of the mouse's colon. Figure 1As shown, compared with the blank control group mice, the colon length of the model group mice was significantly shortened, while after treatment with the low-dose group, medium-dose group and high-dose group, the colon length of the chemotherapy mice increased, and the colon length of the chemotherapy mice in the high-dose group was longer than that of the first control group, the second control group and the third control group, which indicates that the effect of the medicine-food compound of Example 1 is better than the single drug of Control Examples 1 to 3.
[0081] 6. HE staining
[0082] The fixed colon tissue was embedded in paraffin and sliced; the slices were placed in environmentally friendly dewaxing solution I for 20 minutes, environmentally friendly dewaxing solution II for 20 minutes, anhydrous ethanol I for 5 minutes, anhydrous ethanol II for 5 minutes, and 75% alcohol for 5 minutes, and then washed with tap water.
[0083] Table 3 Effects of each group of Chinese medicine preparations on the proliferation of T cells and B cells in chemotherapy mice
[0084]
[0085] Take out from -20℃ refrigerator and restore to room temperature, fix with tissue fixative for 15min, and rinse with running water. Slice into high-definition constant stain pretreatment solution for 1min. Slice into hematoxylin stain solution for 3-5min, wash with tap water, differentiate with differentiation solution, wash with tap water, blue back with blue solution, and rinse with running water. Slice into 95% alcohol dehydration for 1min, and stain in eosin stain solution for 15s. Slice into anhydrous ethanol I 2min, anhydrous ethanol II 2min, anhydrous ethanol III 2min, n-butanol I 2min, n-butanol II 2min, xylene I 2min, xylene II 2min transparent, neutral gum seal. Microscope examination, image acquisition and analysis.
[0086] The results are as follows Figure 2 As shown, the colon mucosal structure of mice in the blank control group was normal, clearly visible, and the villi were intact; the integrity of the colon villi of mice in the model group was destroyed, some of them were necrotic and fell off, and a large number of inflammatory cell infiltrations were visible; the intestinal structure of mice in the low-dose group, medium-dose group, and high-dose group was relatively restored, the degree of damage was lighter than that in the model group, and the villi were relatively intact.
[0087] 7. Real-time fluorescence quantitative PCR (RT-PCR) to determine colon tight junction proteins
[0088] Total RNA from the colon was extracted using FreeZol Reagent, and then reverse transcribed using ExonScript RTSuperMix containing dsDNase. Fast SYBR Green qPCR Master Mix UDG was used to analyze the expression of tight junction proteins ZO-1, Occludin, and Claudin-1 in the mouse colon using qRT-PCR reaction in a real-time PCR system (SLAN-96P, HONGSHI), and GAPDH was used as an internal reference. The primers used were designed and synthesized by Beijing Qingke Biotechnology Co., Ltd. (as shown in Table 4). -ΔΔCt Method for data processing.
[0089] Table 4 Primer sequences
[0090]
[0091] The results are shown in Table 5. In the medium-dose group and the high-dose group, the expression levels of colon ZO-1 in chemotherapy mice were 0.47±0.08 and 0.51±0.10, respectively, and the differences were statistically significant compared with the model group (P<0.05); in the high-dose group, the expression levels of colon ZO-1 in chemotherapy mice were higher than those in the first control group, the second control group and the third control group, which shows that the effect of the medicine-food compound of Example 1 is better than the single drug of Control Examples 1 to 3; in addition, compared with the model group, the relative expression level of colon tight junction protein ZO-1 in the high-dose group increased by 0.20, which is better than the sum of the increases of the first control group, the second control group and the third control group of 0.17, which shows that the medicine-food compound of Example 1 has a synergistic effect on the colon tight junction protein ZO-1 of mice after chemotherapy.
[0092] In the medium-dose group and the high-dose group, the expression levels of colon Claudin-1 in chemotherapy mice were 0.59±0.24 and 0.73±0.24, respectively, and the differences were statistically significant compared with the model group (P<0.05); in the high-dose group, the expression levels of colon Claudin-1 in chemotherapy mice were higher than those in the first control group, the second control group, and the third control group, which indicates that the effect of the medicine-food compound of Example 1 is better than that of the single drugs of Control Examples 1 to 3; in addition, compared with the model group, the relative expression level of colon tight junction protein Claudin-1 in the high-dose group increased by 0.49, which is better than the sum of the increases of the first control group, the second control group, and the third control group by 0.35, which indicates that the medicine-food compound of Example 1 has a synergistic effect on the colon tight junction protein Claudin-1 of mice after chemotherapy.
[0093] In the low-dose group, medium-dose group and high-dose group, the expression levels of colon Occludin in chemotherapy mice were 0.33±0.07, 0.37±0.12 and 0.42±0.06, respectively, and the differences compared with the model group were statistically significant (P<0.05); in the high-dose group, the expression levels of colon Occludin in chemotherapy mice were higher than those in the first control group, the second control group and the third control group, which shows that the effect of the medicine-food compound of Example 1 is better than the single drug of Control Examples 1 to 3; in addition, compared with the model group, the relative expression level of colon tight junction protein Occludin in the high-dose group increased by 0.34, which is better than the sum of the increases of 0.27 in the first control group, the second control group and the third control group, which shows that the medicine-food compound of Example 1 has a synergistic effect on the colon tight junction protein Occludin in mice after chemotherapy.
[0094] Table 5 Effects of each group of Chinese medicine preparations on intestinal tight junction proteins in chemotherapy mice
[0095]
[0096] Note: * indicates P < 0.05 compared with the model group; ** indicates P < 0.01 compared with the model group; *** indicates P < 0.001 compared with the model group; **** indicates P < 0.0001 compared with the model group.
[0097] Therefore, the Chinese medicine composition, Chinese medicine preparation, preparation method and application thereof for improving chemotherapy-induced leukopenia and intestinal mucosal damage provided by the present invention at least achieve the effect of not only improving chemotherapy-induced leukopenia and intestinal mucosal damage, but also improving immunity.
[0098] The above is only a preferred embodiment of the present disclosure. It should be understood that the present disclosure is not limited to the form disclosed herein, and should not be regarded as excluding other embodiments, but can be used in various other combinations, modifications and environments, and can be modified within the scope of the concept described herein through the above teachings or the technology or knowledge of the relevant field. The changes and modifications made by those skilled in the art do not deviate from the spirit and scope of the present disclosure, and should be within the scope of protection of the claims attached to the present disclosure.
Claims
1. A Chinese medicine composition for improving chemotherapy-induced leukopenia and intestinal mucosal damage, characterized in that: The raw materials of the traditional Chinese medicine composition include 7.5 to 30 parts of Tremella fuciformis, 5 to 20 parts of Ganoderma lucidum and 3 to 12 parts of Polygonatum sibiricum by weight.
2. A Chinese medicine preparation for improving chemotherapy-induced leukopenia and intestinal mucosal damage, characterized in that: Prepared from the Chinese medicine composition according to claim 1.
3. The Chinese medicine preparation according to claim 2, characterized in that: The dosage form of the traditional Chinese medicine preparation includes at least one of oral liquid, capsule and granule.
4. A method for preparing the Chinese medicine preparation according to claim 2 or 3, characterized in that: include: Preliminarily drying, crushing and screening the raw materials to obtain powder; The enzyme preparation, water and the powder are mixed, and the mixture is subjected to heat preservation and enzymatic extraction, and then the temperature is raised to perform re-extraction, and then centrifuged and filtered to obtain a filtrate; as well as The filtrate is concentrated, sterilized and dried again to obtain the traditional Chinese medicine preparation.
5. The method according to claim 4, characterized in that The enzyme preparation includes Viscozyme L and β-glucanase.
6. The method according to claim 4, characterized in that The mass ratio of the enzyme preparation, the water and the powder is 1:500-1000:50-100.
7. The method according to claim 4, characterized in that The temperature of the heat preservation enzymatic extraction is 45 to 55° C., and the time of the heat preservation enzymatic extraction is 1 to 3 hours.
8. The method according to claim 4, characterized in that The temperature of the re-extraction is 75-85° C., and the time of the re-extraction is 1-3 hours.
9. The method according to claim 4, characterized in that The screening includes: passing through a 40-60 mesh sieve.
10. Use of the Chinese medicine composition according to claim 1, or the Chinese medicine preparation according to claim 2 or 3, or the method according to any one of claims 4 to 9 in the preparation of at least one of a medicine, a health product and a food for improving chemotherapy-induced leukopenia and / or intestinal mucosal damage.
